Clinical studies of EDT002, a first-in-man TMEM16A potentiator, are planned (NCT04488705) and will necessarily include safety and tolerability considerations since TMEM16A is expressed in many tissues other than those primarily affected in CF [142]. This evidence concerns the gene ANO1 and cystic fibrosis.